Despite major progress in both therapeutic and diagnostic techniques, lung cancer is still
considered the leading cause of cancer mortality in the world due to the ineffectiveness of …

Lung cancer is one of the most lethal diseases worldwide, and the survival rate is less than
15% even after the treatment. Unfortunately, chemotherapeutic treatments for lung cancer …

Cancer is one of the most complex diseases that has resulted in multiple genetic disorders
and cellular abnormalities. Globally, cancer is the most common health concern disease that …

During recent decades there have been remarkable advances and profound changes in
cancer therapy. Many therapeutic strategies learned at the bench, including monoclonal …

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …

Cancer is associated with single or multiple gene defects. Recently, much research has
focused on incorporating genetic materials as one of the means to treat various types of …

Small interfering RNAs (siRNAs) silence the expression of specific target genes by
mediating RNA interference (RNAi) in mammalian cells. siRNAs have not only been widely …

The small interfering RNA (siRNA)‐based therapeutics have raised great attention since the
first RNA interference (RNAi)‐derived drug, patisiran, was approved by the US Food and …

Introduction: Cancer is the leading cause of death worldwide. Current cancer treatments in
the clinic mainly include chemotherapy, radiotherapy and surgery, with chemotherapy being …

RNA interference (RNAi) is an endogenous post-transcriptional gene regulatory mechanism,
where non-coding, double-stranded RNA molecules interfere with the expression of certain …